A prospective, cohort study of efficacy of nivolumab as second-line treatment of patients with metastatic renal cell carcinoma
Latest Information Update: 06 Jul 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 06 Jul 2023 New trial record
- 06 Jun 2023 Primary endpoint (overall survival (OS)) has been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology